The ST2L receptor for interleukin 33 (IL-33) mediates pulmonary inflammation and immune system-related disorders, such as asthma and rheumatoid arthritis. At present, very little is known about the molecular regulation of ST2L expression. Here we found that FBXL19, an 'orphan' member of the Skp1-Cullin-F-box family of E3 ubiquitin ligases, selectively bound to ST2L to mediate its polyubiquitination and elimination in the proteasome. Degradation of ST2L involved phosphorylation of ST2L at Ser442 catalyzed by the kinase GSK3b. Overexpression of FBXL19 abrogated the proapoptotic and inflammatory effects of IL-33 and lessened the severity of lung injury in mouse models of pneumonia. Our results suggest that modulation of the IL-33-ST2L axis by ubiquitin ligases might serve as a unique strategy for lessening pulmonary inflammation. 
A r t i c l e s
Interleukin 33 (IL-33), a relatively recently identified member of the IL-1 family of cytokines, is an endogenous proinflammatory danger signal released from injured or dying host cells 1, 2 . Initially, IL-33 was identified as a nuclear factor expressed in endothelial cells 3 ; however, subsequent studies have found that this cytokine is a highly potent distress signal released from necrotic cells after trauma or infection 4, 5 . IL-33 is sufficient to elicit severe allergic inflammation and induce a sepsis-like state that leads to substantial pulmonary impairment [6] [7] [8] . Those effects seem to be driven by activation of the pathways of the transcription factors NF-κB and AP-1 linked to higher expression of genes encoding the lipopolysaccharide (LPS) receptor TLR, the coreceptor CD14 and the adaptor MyD88 (refs. 9,10) . Inhibition of IL-33 by administration of neutralizing antibody to IL-33 (anti-IL-33) or of IL-33 decoy receptors attenuates lung inflammation in mouse models 7, 11 . IL-33-deficient mice also show both less mortality and cytokine release in the LPS-induced model of sepsis 12 , which suggests that endogenous IL-33 has a critical role as a proximal effector in sepsis. Those results contrast with another study demonstrating that exogenous IL-33 attenuates sepsis by enhancing the influx of neutrophils to the site of infection 13 . Such disparate results among studies could be explained by the model systems used and route of IL-33 administration. Nevertheless, these observations as a whole suggest that modulation of the axis of IL-33 and its receptor might serve as a useful strategy for limiting the severity of pulmonary inflammation.
ST2, a member of the family of IL-1 receptors, has been identified as the receptor for IL-33 and consists of two main isoforms: a soluble, secreted form (sST2) and a transmembrane, long form (ST2L) 14, 15 . These isoforms, sST2 and ST2L, have diametrically opposed effects on inflammatory responses. The secreted form, sST2, binds to IL-33 and functions as an inhibitor of IL-33 signals and thus has antiinflammatory properties 11, 16 . In contrast, ST2L is the cognate receptor for IL-33 and is actively expressed by effector cells of the immune response and has a critical role in triggering inflammation [17] [18] [19] . ST2L is a classic type I membrane receptor that contains three extracellular immunoglobulin G (IgG)-like domains, a transmembrane domain and an intracellular Toll-IL-1 receptor domain. ST2L localizes on the surface of a variety of cell types, including lung epithelia and endothelia 20 . IL-33 induces secretion of IL-8 by airway epithelial and pulmonary endothelial cells 20 . As the proinflammatory effects of extracellular IL-33 are achieved through ligation to ST2L, studies assessing the regulation of ST2L protein expression may idenitfy important molecular cues that serve as a basis for the abrogation of IL-33 signaling.
The ubiquitin-proteasome system degrades most intracellular proteins, including membrane-surface receptors [21] [22] [23] [24] . Three enzyme complexes (E1, E2 and E3) are involved in linking ubiquitin chains onto target proteins 25 . Among the families of E3 ubiquitin ligases, the Skp1-Cullin-1-F-box protein (SCF) ligase complex is one of the largest 26 ; in this complex, the F-box protein is the substrate-recognition component. Over 60 F-box proteins have been identified, but only a few, such as β-Trcp and FBXW7, are well characterized. F-box proteins have two main domains: an F-box motif and a substratebinding motif. F-box proteins use their F-box motif to bind to Skp1 A r t i c l e s and assemble the SCF ligase complex, whereas the substrate-binding motif is used for recognition and interaction with phosphorylated substrates 27 . Through an in silico search, the 'orphan' F-box protein FBXL19, has been identified 28 . FBXL19 has considerable sequence similarity to other SCF proteins 28 ; however, the verification of FBXL19 as an SCF E3 subunit, its regulation and molecular targets remain to be determined. Here we found that FBXL19 targeted the IL-33-ST2L axis, selectively mediating the ubiquitination and degradation of ST2L to limit IL-33-induced pulmonary inflammation. Phosphorylation of ST2L mediated by the glycogen synthase kinase GSK3β provided a phosphodegron molecular signal (phosphorylation-dependent degradation motif ) for the binding of ST2L to FBXL19. Our results might serve as a basis for the development of new approaches to lessen the severity of inflammation through the use of components of the ubiquitin-proteasomal machinery to modify the availability of an indispensable receptor linked to sepsis-induced lung injury.
RESULTS

FBXL19 mediates ubiquitination and degradation of ST2L
In the process of investigating the role of IL-33-ST2L in airway inflammation, we first assessed the stability of ST2L. Treatment of MLE12 mouse lung epithelial cells with the protein-biosynthesis inhibitor cycloheximide (20 µg/ml) diminished ST2L mass in a time-dependent manner and demonstrated that endogenous ST2L had a half-life of ~5 h (Fig. 1a,b) . To identify which pathway is involved in the degradation of ST2L, we exposed MLE12 cells to inhibitors of proteasomes (MG-132) or lysosomes (leupeptin) before cycloheximide treatment. MG-132 (20 µM) attenuated the degradation of ST2L, but leupeptin (100 µM) did not (Fig. 1a,b) . Overexpressed mouse ST2L with a green fluorescent protein tag localized in the plasma membrane and cytoplasm, but it did not localize in lysosomes (data not shown). These results suggested that degradation of ST2L was mediated by the proteasome. As ubiquitination is a sorting signal for targeting to the proteasome, we next investigated if ST2L is modified by ubiquitination. We immunoprecipitated ubiquitin from cell lysates, followed by immunoblot analysis of ST2L; this demonstrated that ST2L was polyubiquitinated ( Fig. 1c) and that the ubiquitin chain had, at least in part, the classic Lys48 linkage (Supplementary Fig. 1a) . Furthermore, overexpression of hemagglutinin-tagged ubiquitin induced degradation of ST2L and total ubiquitination of proteins, as assessed in whole-cell lysates (Fig. 1d) . These results indicated that ST2L was degraded by the ubiquitin proteasomal machinery in a lung epithelial cell line.
F-box proteins in the SCF E3 ligase complex recognize and bind specific substrates 27 . Using an unbiased screen, we began to identify which F-box protein targets ST2L. We overexpressed more than 30 F-box proteins, then assessed the abundance of ST2L. Among five such F-box proteins, only ectopic expression of V5-tagged FBXL19 (FBXL19-V5) resulted in lower abundance of immunoreactive ST2L (Fig. 1e) . In addition, ectopic expression of FBXL19-V5 diminished ST2L protein in a dose dependent manner, but sST2 did not (Fig. 1f) . In primary cultures of human bronchial epithelial cells (HBEpCs) and human pulmonary artery endothelial cells (HPAECs), overexpression of FBXL19 also resulted in less ST2L protein (Fig. 1g,h) . Knockdown of FBXL19 with short hairpin RNA (shRNA) targeting FBXL19 attenuated the degradation of ST2L (Fig. 1i) , concomitant with lower expression of FBXL19 mRNA and protein ( Supplementary  Fig. 2 ). The FBXL19-V5-mediated degradation of ST2L was attenuated by proteasomal blockade with MG-132 (Fig. 1j ). An FBXL19 variant lacking the F-box motif was unable to bind Skp1 (Supplementary Fig. 3 ). 
A r t i c l e s
Transfection of plasmid encoding wild-type FBXL19-V5 or an FBXL19 variant with truncation at the NH 2 terminus that still contained the F-box motif resulted in lower ST2L expression; however, overexpression of an FBXL19 variant that lacked the F-box motif had no effect on ST2L protein (Fig. 1k,l) . Together these results indicated that FBXL19 is a component of an SCF complex that mediates proteasomal degradation of ST2L.
IL-33 diminishes ST2L expression
Next we assessed ligand-induced degradation of ST2L, because turnover of cell-surface receptors in response to engagement of ligands is important in controlling receptor expression and intracellular signaling 29 . Treatment of MLE12 cells with IL-33 diminished the signal intensity of ST2L on the cell surface, as assessed by immunoblot analysis (Fig. 2a) , flow cytometry (showing ST2L on the surface of control cells, but a left shift of the curve (less STL2) after IL-33 treatment; Fig. 2b ) and fluorescence microscopy (without permeabilization; Fig. 2c ). To investigate if the lower abundance of cell-surface ST2L was due to internalization and/or degradation of the receptor, we examined the trafficking of ST2L and ST2L protein mass in whole-cell lysates after treatment with IL-33. IL-33 induced the internalization of ST2L (data not shown) and decreased ST2L mass in MLE12 cells in a dose-and time-dependent manner ( Fig. 2d,e) . In addition, treatment with IL-33 resulted in lower expression of ST2L protein in primary cultures of human small-airway epithelial cells or rat alveolar type II epithelial cells (Supplementary Fig. 1b ), which indicated a more widespread ability of IL-33 to rapidly trigger degradation of ST2L in lung epithelium via binding of the ligand to its receptor. IL-33 had no effect on the expression of the related receptor IL-1R1 (Fig. 2a,f) , and IL-1β had no effect on ST2L expression (Fig. 2g) , which suggested that IL-33 specifically induced the degradation of ST2L.
FBXL19 mediates IL-33-induced degradation of ST2L
To identify which proteolytic pathway is involved in the degradation of ST2L, we exposed cells to MG-132 or leupeptin before treatment with IL-33. Pretreatment with MG-132 attenuated the IL-33-induced degradation of ST2L, but pretreatment with leupeptin did not (Fig. 3a,b) , which suggested that the IL-33-induced degradation of ST2L was mediated by the proteasome. Further, IL-33 induced polyubiquitination of ST2L in a time-dependent manner, as assessed by immunoprecipitation with anti-ubiquitin and immunoblot analysis of ST2L (Fig. 3c) . Thus, IL-33-induced degradation of ST2L was mediated by the ubiquitin-proteasome pathway. Knockdown of FBXL19 by transfection of FBXL19-specific shRNA attenuated IL-33-induced ubiquitination and degradation ST2L, and the effects of this were reversed by overexpression of FBXL19-V5 ( Fig. 3d-f) . These results suggested that the IL-33-induced degradation of ST2L was mediated by FBXL19 and was perhaps acting as part of a feedback control mechanism to regulate steady-state amounts of the receptor for IL-33.
GSK3b regulates phosphorylation and degradation of ST2L
Protein phosphorylation can serve as a molecular signal for ubiquitination by the E3 enzyme complex 27 . To investigate whether the degradation of ST2L was dependent on its phosphorylation, we first determined if ST2L was phosphorylated in response to treatment with IL-33. Immunoprecipitation indicated that IL-33 induced serinephosphorylation of both endogenous ST2L (Fig. 4a) and overexpressed Flag-tagged mouse ST2L (Fig. 4b) in a time-dependent manner. GSK3β regulates the phosphorylation and degradation of proteins 29, 30 . ST2L contains a consensus sequence motif (Ser442-X-X-X-Ser446, where 'X' indicates any amino acid) for phosphorylation by GSK3β 30, 31 . Therefore, we next determined whether GSK3β has a role in the phosphorylation and degradation of ST2L. Treatment of MLE12 cells with IL-33 induced the tyrosine-phosphorylation of GSK3β (an active form; Fig. 4c ). Transfection of plasmid encoding wild-type GSK3β or a constitutively active form of GSK3β induced the phosphorylation and degradation of ST2L (Fig. 4d) . Knockdown of GSK3β by through the use of small interfering RNA (siRNA) targeting GSK3β effectively attenuated IL-33-induced serinephosphorylation of ST2L (Fig. 4e) , which suggested that the IL-33-induced phosphorylation of ST2L was mediated by GSK3β. Further, knockdown or inhibition of GSK3β was sufficient to abrogate the effects of GSK3β on the IL-33-induced degradation of ST2L (Fig. 4f,g ). To investigate whether activation of GSK3β regulated the binding of FBXL19 to ST2L, we transfected MLE12 cells with plasmid encoding Flag-tagged mouse ST2L, then treated the cells with the GSK3β inhibitor TWS119 before transfecting them with plasmid encoding FBXL19-V5. Inhibition of GSK3β blocked the binding of FBXL19-V5 to Flag-tagged ST2L (Fig. 4h) . Furthermore, knockdown of GSK3β blocked the IL-33-induced ubiquitination of ST2L (Fig. 4i) . 
A r t i c l e s
To identify sites in ST2L for phosphorylation by GSK3β, we transfected cells with plasmid encoding either of two candidate ST2L variants, ST2L(S442A) and ST2L(S547A), that contain substitutions at putative sites for phosphorylation by GSK3β. Although IL-33 induced the degradation of wild-type ST2L and ST2L(S547A), it did not alter the steady-state amount of the immunoreactive ST2L(S442A) mutant (Fig. 5a) . Recombinant GSK3β phosphorylated Flag-tagged mouse ST2L but not ST2L(S442A) (Fig. 5b) . Treatment with IL-33 did not induce serine-phosphorylation (data not shown) or ubiquitination (Fig. 5c ) of the ST2L(S442A) mutant. Further, when we cotransfected cells with plasmid encoding FBXL19-V5 plus plasmid encoding Flagtagged ST2L or ST2L(S442A), the ST2L(S442A) variant showed less interaction with FBXL19-V5, as assessed by coimmunoprecipitation (Fig. 5d) . Hence, the association of FBXL19 with ST2L required a critical phosphorylation-acceptor site to mediate the ubiquitination and degradation of ST2L. These results suggested that GSK3β phosphorylated ST2L at Ser442 and regulated the stability of the receptor in lung epithelia.
ST2L has a ubiquitination and docking site for FBXL19
To identify putative ubiquitin-acceptor sites in ST2L, we substituted several candidate lysine residues of mouse ST2L with arginine (substitutions in parentheses below). Of several mutants tested, only ST2L(K326R) showed stability in response to treatment with cycloheximide; wild-type ST2L and ST2L(K246R) did not (Fig. 6a,b) . Overexpression of FBXL19-V5 resulted in lower expression of wildtype ST2L and ST2L(K246R) but not ST2L(K326R) (Fig. 6c) . In vitro ubiquitination assays that included the full complement of reaction npg components (E1, E2, FBXL19, Skp1, Cullin-1, ubiquitin and ATP) and recombinant substrates showed that FBXL19 ubiquitinated wildtype ST2L and ST2L(K246R) but not ST2L(K326R) (Fig. 6d) . Thus, Lys326 was a critical residue for site-specific polyubiquitination of mouse ST2L.
Next we investigated where FBXL19 binds in the ST2L sequence (the docking site for FBXL19). We generated several deletion mutants of mouse ST2L with carboxy-terminal Flag tags (Supplementary Fig. 4a ) and incubated those with lysates of HEK293 human embryonic kidney cells expressing histidine-tagged FBXL19. After precipitation with histidine-coated beads, only the Flag-tagged mutant ST2L(C328) with deletion at the carboxyl terminus showed very limited ability to interact with FBXL19 ( Supplementary Fig. 4b) , which suggested the FBXL19 bound to ST2L in the carboxyl terminus of ST2L.
FBXL19 blocks IL-33-mediated apoptosis
IL-33 is a proinflammatory cytokine that induces T helper type 2-associated immune responses 1, 18, 19 , enhances LPS-induced release of cytokines 9, 10, 12, 20 and promotes cell death 32, 33 ; however, its effect on distal lung epithelium has not been investigated. Cortactin, an oncogenic-like protein that regulates cell motility and proliferation, is degraded during cell death 34 . Overexpression of cortactin attenuates detachment-induced apoptosis in head and neck squamous-cell carcinoma cells 35 , whereas cortactin depletion can promote apoptosis 36 ; hence, cortactin might regulate cellular lifespan. IL-33 induced serine-phosphorylation and degradation of cortactin in MLE12 cells (Fig. 7a,b) , which suggested that this process might induce apoptosis. We measured apoptosis by staining with annexin V-propidium iodide, in which staining with both reagents indicates late apoptotic cells, and staining with annexin V plus lack of staining with propidium iodide indicates early apoptotic cells. This showed that treatment for 6 h with IL-33 (10 ng/ml) induced apoptosis of MLE12 cells (Fig. 7c) . Overexpression of cortactin attenuated the IL-33-induced apoptosis of cells (Fig. 7d) . Thus, these results suggested that IL-33-induced cell death might be mediated by degradation of cortactin. Notably, overexpression of FBXL19-V5 attenuated the IL-33-induced degradation of cortactin in MLE12 cells (Fig. 7e,f) , HBEpCs and HPAECs (Supplementary Fig. 5a ) and apoptosis of MLE12 cells (Fig. 7g) and HBEpCs (Supplementary Fig. 5b ). IL-33 induces the release of cytokines such as IL-8 and IL-6 from human lung epithelial and endothelial cells 20 . We found that ectopically expressed FBXL19-V5 abrogated the IL-33-induced release of IL-8 from HBEpCs and of IL-6 from HPAECs (Supplementary Fig. 5c ). IL-33 also increases vascular endothelial permeability, a key proinflammatory effect 17 . Notably, overexpression of FBXL19-V5 blocked the IL-33-induced barrier disruption and stress-fiber formation of HPAECs ( Supplementary  Fig. 5d,e) . These data together suggested that although endogenous FBXL19 normally mediated the effects of IL-33 on the ubiquitination of ST2L (Fig. 3d) and steady-state turnover of ST2L (Fig. 3e) , supraphysiological concentrations of the F-box protein might impair IL-33 signaling by depleting the availability of its cognate receptor.
FBXL19 prevents endotoxin-induced acute lung injury
Intratracheal administration of LPS for 24 h, at a dose of 1 mg per kg body weight, or of Pseudomonas aeruginosa (strain PA103) for 24 h, at a dose 4 × 10 4 colony-forming units per mouse, to C57/BL6 mice resulted in a higher concentration of IL-33 in bronchoalveolar lavage (BAL) fluid than that in mice treated with PBS (Fig. 8a) . To investigate the effects of FBXL19 on endotoxin-induced lung injury, we treated mice by intratracheal administration of a lentiviral vector encoding a fusion of FBXL19 and red fluorescent protein or a control lentiviral vector encoding the red fluorescent protein only 
and analyzed in vivo expression of these constructs in lung tissue by fluorescence scanning (Fig. 8b) . Overexpression of FBXL19 diminished ST2L expression in lung tissue to a degree similar to the effects of challenge with IL-33 (for 24 h at a dose of 4 µg per mouse) on ST2L expression in lung tissue (Supplementary Fig. 6a ). Intratracheal challenge with IL-33 triggered apoptosis of lung epithelial cells, as measured by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL; ~42% of intratracheal LPS-induced cell death; Supplementary Fig. 6b,c) . However, overexpression of FBXL19 in mice blocked the cell death (Fig. 8c,d ) and inflammatory cellular infiltration (Supplementary Fig. 6d ) induced by intratracheal challenge with IL-33. Furthermore, lentiviral overexpression of FBXL19 effectively attenuated the pulmonary inflammation, as assessed histologically (Fig. 8e,f) , and the alveolar protein leakage (Fig. 8g) induced by LPS or P. aeruginosa (strain PA103), and also resulted in less induction of IL-6 ( Fig. 8h) and tumor necrosis factor (Fig. 8i) in BAL fluid by LPS or P. aeruginosa (strain PA103). In vivo knockdown of FBXL19 with lentivirus expressing FBXL19-specific shRNA promoted the intratracheal LPS-mediated induction of IL-6 in BAL fluid (Supplementary Fig. 7a ) and augmented appearance of pulmonary infiltrates, as assessed histologically ( Supplementary  Fig. 7b,c) . This technique substantially diminished steady-state FBXL19 mRNA in vivo (Supplementary Fig. 7d ). To investigate whether the effects of FBXL19 were specific to IL-33-ST2L, we examined effects of overexpression of FBXL19 on IL-1R1 expression and IL-1β signaling. Overexpression of FBXL19-V5 had no effect on IL-1R1 expression or IL-1β-induced signaling, such as activation of the kinase Erk1-Erk2 (Supplementary Fig. 8a,b) . The administration of FBXL19 had no effect on inflammatory cellular infiltration induced by intratracheal IL-1β (Supplementary Fig. 8c ). These results suggested that FBXL19 blocked the integrity of the IL-33-ST2L axis by selectively promoting the degradation of a key receptor to abrogate sepsis-induced lung injury.
DISCUSSION
The ligation of IL-33 to its receptor ST2L is crucial, as it has an important role in the pathogenesis of immune system-related disorders, such as asthma and rheumatoid arthritis, as well as septic lung injury 6, 37, 38 . Understanding the regulation of ST2L expression is essential for identifying the molecular targets that mediate proinflammatory signaling by IL-33. Here we have shown that ST2L is a phosphorylated receptor regulated by IL-33 at the post-translational level through its steady-state processing by F-box protein FBXL19, a prototypical SCF subunit that was both sufficient and required to mediate ubiquitination and degradation of ST2L in lung epithelia. The ubiquitination activity of FBXL19 was facilitated by GSK3β, which generated a phosphodegron-like molecular signature in ST2L, leading to its proteasomal degradation. Hence, we used FBXL19 to modulate the IL-33-receptor axis. Indeed, ectopic expression of FBXL19 attenuated a previously unrecognized effect of IL-33 on apoptosis and, notably, limited the severity of endotoxin-and P. aeruginosa-induced inflammatory lung injury. Whether our results might translate to newer approaches for the treatment of pneumonia remains speculative, but they indicate that the delivery of small-molecule agonists to enhance or mimic the actions of FBXL19 in the IL-33-ST2L axis might be a means of more precisely lessening inflammation. The internalization, mono-or polyubiquitination and degradation of cytokine receptors are well-described processes for feedback regulation of ligand-induced signaling events 29 ; however, the internalization and post-translational modification of ST2L has not been studied so far, to our knowledge. Our results have shown that under steady-state conditions, ST2L was gradually internalized and degraded (half-life, ~5 h) and exceeded the stability of some surface receptors, such as the G protein-coupled estrogen receptor 11 . After ligation of IL-33 to endogenous ST2L, however, surface expression rapidly decreased, consistent with the processing of the related cytokine receptors IL-5R 23 , IL-17R 39 , IL-2Rβ 21 and the common γ-chain 22 after ligand engagement. Some type I receptors that undergo endocytosis and degradation also have ubiquitin-binding motifs in their cytosolic tails that serve as recognition signals for the SCF β-Trcp ligase 40 . Likewise, FBXL19 interacted with the carboxy-terminal region of ST2L to facilitate polyubiquitination at Lys326. Whether ST2L has a distinct ubiquitin-dependent endocytosis-like motif that engages an F-box protein or interacts with endocytic adaptors through ubiquitin-binding domains to promote proteasomal sorting requires further evaluation.
There are very limited data on the role of F-box proteins in the ubiquitination and degradation of cytokine receptors, although several RING-finger E3 ligases, such as TRAF6 (ref. 39 ), c-Cbl 22 and RNF41 (ref. 24) , regulate the turnover of cytokine receptors. Phosphorylation is an initial step for the recruitment of many F-box proteins to interact with target substrates and transfer ubiquitin to those target substrates, and the molecular activity of FBXL19 resembles the canonical recognition of phosphodegrons by SCF proteins 27 . For example, activation of protein kinase C enhances the phosphorylation and degradation of the receptor IL-8RB 41 , and kinases of the Jak family control the ubiquitination and degradation of the receptor IL-5R 23 and the receptor for leptin 24 . The phosphorylation of substrates by GSK3β is directed in part by the minimal-recognition motif Ser-X-X-X-Ser. Here, activation of GSK3β induced the phosphorylation of ST2L at Ser442 to facilitate docking of FBXL19 in the receptor, which thereby mediated the ubiquitination and degradation of ST2L. These results support the emerging proposal of a role for GSK3β in controlling the lifespan of surface receptors with divergent roles, such as DR5 (ref. 42 ) and the receptor for prolactin 43 .
IL-33 is an important distress signal or 'alarmin' released from damaged endothelial or epithelial cells that potently induces the activation of inflammasomes 44 and promotes the release of cytokines (such as IL-5, IL-6, IL-8 and IL-13) from a variety of cell types 44 , including epithelial and endothelial cells 20 . Mounting data also suggest that IL-33 regulates cellular lifespan, as shown by the ability of inhibition of IL-33 to provide protection against cisplatin-induced apoptosis of kidney tubule epithelial cells 32 . IL-33 also enhances the apoptosis of human eosinophils mediated by the lectin Siglec-8 (ref. 33) . Our study has supported those published observations by showing that IL-33 induced apoptosis of lung epithelium and that this effect was controlled by alteration of receptor concentrations.
Our study has highlighted the finding that manipulation of the proteolytic processing of a surface receptor by ubiquitin-mediated degradation was sufficient to profoundly attenuate cytokine-mediated pulmonary inflammation by endotoxin-containing pathogens. It has been shown that downregulation of ST2L by siRNA blocks the effects of IL-33-induced release of cytokines from pulmonary epithelial and endothelial cells 20 , which emphasizes the biological role of the ligation of IL-33 to its receptor in the lung. Although abrogation of IL-33 signaling through the use of knockout mice, neutralizing antibodies or sST2 decoy receptors has been described before, identifying the substrate-recognition specificity of FBXL19 might represent a more elegant strategy for attenuating the IL-33-ST2L pathway. Typically, F-box proteins (such as FBW7 and β-Trcp) have many divergent substrates; thus, we cannot exclude the possibility of other molecular targets, and we do not mean to imply that ST2L is the only substrate for FBXL19. Nevertheless, our fundamental observation was that FBXL19 attenuated IL-33-mediated activity by removing ST2L, but not sST2 or IL-1R1, on the cell surface, a critical initial step that led to profound biological consequences. Future studies should focus on high-throughput screening of peptide mimics of FBXL19 to attenuate inflammation in bacterial pneumonia that exploits molecular interactions in the IL-33-ST2L→GSK3β→FBXL19 pathway.
METHODS
Methods and any associated references are available in the online version of the paper. 
